127 related articles for article (PubMed ID: 31243337)
1. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.
Canter DJ; Freedland S; Rajamani S; Latsis M; Variano M; Halat S; Tward J; Cohen T; Stone S; Schlomm T; Bishoff J; Bardot S
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):102-107. PubMed ID: 31243337
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
[TBL] [Abstract][Full Text] [Related]
3. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
4. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
[TBL] [Abstract][Full Text] [Related]
5. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.
Cuzick J; Stone S; Fisher G; Yang ZH; North BV; Berney DM; Beltran L; Greenberg D; Møller H; Reid JE; Gutin A; Lanchbury JS; Brawer M; Scardino P
Br J Cancer; 2015 Jul; 113(3):382-9. PubMed ID: 26103570
[TBL] [Abstract][Full Text] [Related]
6. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.
Bishoff JT; Freedland SJ; Gerber L; Tennstedt P; Reid J; Welbourn W; Graefen M; Sangale Z; Tikishvili E; Park J; Younus A; Gutin A; Lanchbury JS; Sauter G; Brawer M; Stone S; Schlomm T
J Urol; 2014 Aug; 192(2):409-14. PubMed ID: 24508632
[TBL] [Abstract][Full Text] [Related]
7. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
[TBL] [Abstract][Full Text] [Related]
8. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
Freedland SJ; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Gutin A; Sangale Z; Lanchbury JS; Salama JK; Stone S
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):848-53. PubMed ID: 23755923
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy.
Shangguan X; Qian H; Jiang Z; Xin Z; Pan J; Dong B; Xue W
J Cancer Res Clin Oncol; 2020 Mar; 146(3):687-694. PubMed ID: 31745702
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
11. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
12. Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.
Koch MO; Cho JS; Kaimakliotis HZ; Cheng L; Sangale Z; Brawer M; Welbourn W; Reid J; Stone S
Cancer Biomark; 2016 Jun; 17(1):83-8. PubMed ID: 27314296
[TBL] [Abstract][Full Text] [Related]
13. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
14. Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.
Cuzick JM; Stone S; Lenz L; Flake DD; Rajamani S; Moller H; Berney DM; Cohen T; Scardino PT
Cancer Rep (Hoboken); 2022 Aug; 5(8):e1535. PubMed ID: 34423592
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
Cuzick J; Swanson GP; Fisher G; Brothman AR; Berney DM; Reid JE; Mesher D; Speights VO; Stankiewicz E; Foster CS; Møller H; Scardino P; Warren JD; Park J; Younus A; Flake DD; Wagner S; Gutin A; Lanchbury JS; Stone S;
Lancet Oncol; 2011 Mar; 12(3):245-55. PubMed ID: 21310658
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.
Tward J; Lenz L; Flake DD; Rajamani S; Yonover P; Olsson C; Kapoor DA; Mantz C; Liauw SL; Antic T; Fabrizio M; Salzstein D; Shore N; Albertson D; Henderson J; Lee SP; Gay HA; Michalski J; Hung A; Raben D; Garraway I; Lewis MS; Nguyen PL; Marshall DT; Brawer MK; Stone S; Cohen T
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):66-76. PubMed ID: 34610388
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
Cuzick J; Berney DM; Fisher G; Mesher D; Møller H; Reid JE; Perry M; Park J; Younus A; Gutin A; Foster CS; Scardino P; Lanchbury JS; Stone S;
Br J Cancer; 2012 Mar; 106(6):1095-9. PubMed ID: 22361632
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.
Léon P; Cancel-Tassin G; Drouin S; Audouin M; Varinot J; Comperat E; Cathelineau X; Rozet F; Vaessens C; Stone S; Reid J; Sangale Z; Korman P; Rouprêt M; Fromond-Hankard G; Cussenot O
World J Urol; 2018 Sep; 36(9):1495-1500. PubMed ID: 29679140
[TBL] [Abstract][Full Text] [Related]
19. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
20. Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy.
Tward JD; Schlomm T; Bardot S; Canter DJ; Scroggins T; Freedland SJ; Lenz L; Flake DD; Cohen T; Brawer MK; Stone S; Bishoff J
Clin Genitourin Cancer; 2021 Aug; 19(4):296-304.e3. PubMed ID: 33608228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]